New software could help doctors make smarter prostate cancer treatment decisions

NCT ID NCT06815354

Recruiting now Diagnosis Sponsor: AIQ Solutions Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a software tool called TRAQinform Theranostics that analyzes PET/CT scans to help doctors decide on treatment for metastatic prostate cancer. Researchers will see if having this extra information changes the treatment plan. The study involves 32 patients starting a specific therapy (177Lu-PSMA). It is not testing a new drug, but rather a new way to interpret existing scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRAQinform Theranostics (software device)
What this could lead to: If successful, this tool could help doctors choose more effective treatments for prostate cancer by better analyzing scan results.
What could go wrong: This is a small, early study (32 people) that only looks at whether doctors change their minds, not whether patients actually do better. The tool may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Weill Medical College of Cornell
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.